Reports
Published: 2018-11-22 09:03:45
Scandion Oncology A/S (”Scandion Oncology”) herby reports interim report for Q3 2018.
Third quarter (30-JUL-2018 – 30-SEP-2018) Net sales 0 (0) Result after tax decreased to -1,013,567 (-422,162) Result per share decreased to -0.14 (-0.06) Equity ratio amounted to -0.84 (0.22) Nine months (01-JAN-2018 – 30-SEP-2018) Net sales 0 (0) Result after tax decreased to -4,361,298 (-541,233) Result per share decreased to -0.46 (-0.06) Equity ratio amounted to -0.84 (0.22) Highlights during Q3 2018 Highlights after the balance sheet date For further information regarding Scandion Oncology, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells.